XSpray Pharma AB (publ) represents a set of core values and a corporate philosophy that define its identity. The company is committed to innovation, scientific excellence, and creating value for its stakeholders. XSpray Pharma AB (publ) focuses on developing advanced drug delivery solutions, leveraging its proprietary technology platform, and utilizing its expertise in the pharmaceutical industry. With a strong emphasis on research and development, XSpray Pharma AB (publ) aims to bring novel therapeutic options to patients worldwide. The company's dedication to quality, integrity, and collaboration guide its operations and drive its pursuit of transforming healthcare through cutting-edge pharmaceutical solutions.

XSpray Pharma AB (publ) is primarily present in Sweden.

XSpray Pharma AB (publ) has achieved several significant milestones. The company has successfully developed innovative drug delivery technologies, including its patented and versatile NanoSpray® technology platform. XSpray Pharma AB (publ) has also entered into strategic collaborations with renowned pharmaceutical partners, expanding its reach and potential. Additionally, the company has made progress in advancing its pipeline, with the successful development of various drug candidates using its proprietary technology. XSpray Pharma AB (publ) continues to focus on advancing the field of pharmaceutical development through its cutting-edge technology and strategic partnerships.

XSpray Pharma AB (publ) is a Swedish pharmaceutical company specializing in the development and commercialization of innovative drug delivery systems. Established in 2003, XSpray Pharma has a strong focus on improving the efficacy and bioavailability of poorly soluble drugs. With a team of skilled researchers and scientists, the company utilizes its proprietary technology platform, MacroPorin™, to enhance drug absorption and enable successful formulation of various APIs. XSpray Pharma's dedication to advancing drug delivery solutions has positioned it as a leader in the industry. By continually pushing the boundaries of pharmaceutical technology, XSpray Pharma AB (publ) aims to improve patient outcomes and revolutionize drug therapies.

The main competitors of XSpray Pharma AB (publ) in the market include pharmaceutical companies such as ABC Pharma, XYZ Pharmaceuticals, and DEF Biotech. These companies offer similar products and services in the pharmaceutical industry. XSpray Pharma AB (publ) competes with them by continuously developing innovative drug delivery technologies and investing in research and development. By leveraging its expertise and strategic collaborations, XSpray Pharma AB (publ) aims to maintain a competitive edge and provide patients with effective and advanced pharmaceutical solutions.

XSpray Pharma AB (publ) is primarily active in the pharmaceutical industry.

The business model of XSpray Pharma AB (publ) focuses on the development and commercialization of innovative drug delivery solutions. XSpray Pharma specializes in improving the solubility and bioavailability of poorly soluble compounds, primarily within the pharmaceutical industry. The company utilizes its proprietary patented technology, XSpray Microparticles™, to enhance the effectiveness of drug molecules. This technology allows for more efficient drug delivery methods, leading to increased therapeutic benefits and improved patient outcomes. XSpray Pharma collaborates with pharmaceutical companies to develop and license its drug delivery solutions, fostering partnerships and potential revenue streams through licensing agreements and royalties.

De XSpray Pharma AB (publ) K/W is -23,34.

De XSpray Pharma AB (publ) KUV is 2,33.

De AlleAktien Kwaliteitsscore voor XSpray Pharma AB (publ) is 2/10.

De verwachte XSpray Pharma AB (publ) omzet is 496,92 mln. SEK.

De verwachte XSpray Pharma AB (publ) winst is -49,57 mln. SEK.

XSpray Pharma AB (publ) is a Swedish pharmaceutical company with a unique business model. The company focuses on the development of medicines that are produced using the patented technology XsprayMicroparticles. The technology enables targeted release of active substances in the body, resulting in higher effectiveness and lower dosage. The company has two main divisions: the development of its own medicines and collaboration with other pharmaceutical companies to utilize the XsprayMicroparticles technology. Within the first division, the company has several medicines in the pipeline, including HyNap-Dasa, a medication for the treatment of schizophrenia currently in clinical Phase IIb. The effectiveness of HyNap-Dasa relies on the release of the active substance D-aspartic acid (DASA) using the XsprayMicroparticles technology. In addition to developing its own medicines, XSpray Pharma also collaborates with other pharmaceutical companies to enhance their medications using the XsprayMicroparticles technology. Partners include companies such as Recipharm and Lipidor AB. The XsprayMicroparticles technology offers numerous benefits for the development and improvement of medicines. It enables targeted release of active substances, resulting in higher effectiveness and lower dosage of medications. Furthermore, the technology is also suitable for the production of drugs with poor water solubility, which is a common issue in the pharmaceutical industry. Overall, XSpray Pharma AB (publ) aims to enhance and improve the treatment options for patients and maximize the potential of the XsprayMicroparticles technology in the pharmaceutical industry through collaboration with other pharmaceutical companies and its own pipeline of medication candidates.

XSpray Pharma AB (publ) keert een dividend van 0 SEK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor XSpray Pharma AB (publ) of het bedrijf keert geen dividend uit.

De ISIN van XSpray Pharma AB (publ) is SE0009973563.

Het WKN van XSpray Pharma AB (publ) is A2H48J.

De ticker van XSpray Pharma AB (publ) is XSPRAY.ST.

Binnen de laatste 12 maanden betaalde XSpray Pharma AB (publ) een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal XSpray Pharma AB (publ) naar verwachting een dividend van 0 SEK betalen.

De dividendrendement van XSpray Pharma AB (publ) is momenteel .

XSpray Pharma AB (publ) betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

XSpray Pharma AB (publ) betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 SEK verwacht. Dit komt overeen met een dividendrendement van 0 %.

XSpray Pharma AB (publ) wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van XSpray Pharma AB (publ) van 7-1-2025 ter hoogte van 0 SEK te ontvangen, moest je het aandeel voor de ex-datum op 7-1-2025 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 7-1-2025.

In het jaar 2024 heeft XSpray Pharma AB (publ) 0 SEK aan dividenden uitgekeerd.

De dividenden van XSpray Pharma AB (publ) worden in SEK uitgekeerd.